About
CellType is building a biological world model and agentic drug-discovery company: AI agents run discovery workflows on foundation models trained on human cellular and molecular data. It sells to pharmaceutical and biotech teams, differentiating through whole-system human-biology simulation—including cells, tissues, microenvironments, and drug-cell interactions—rather than relying primarily on protein-centric or animal proxies.
Market
CellType competes in AI-native drug discovery and life-sciences software, positioning itself as a biological world model and agentic platform that turns cellular and molecular data into drug-development decisions. Its differentiation is an emphasis on simulating human biology and improving translation—predicting drug response, toxicity, patient variation, diagnostics, and longitudinal signals, then selecting the next experiment—rather than focusing only on molecule design. The competitive set includes broad AI drug-discovery platforms such as Recursion, Insilico, and Isomorphic Labs, computational molecular-discovery platforms such as Schrödinger, and other AI biotech platforms such as Owkin and Atomwise; CellType’s wedge is the human-biology and patient-signal layer combined with automated discovery workflows.
Primary customers are pharmaceutical and biotechnology R&D organizations—especially large pharmaceutical companies and biotech teams seeking to de-risk drug discovery and development. Likely buyers are drug-discovery, translational-biology, and clinical-development leaders with a target, program, assay, or patient question.
At a Glance
Problem
Drug discovery is expensive and risky because signals found in preclinical models often fail to translate into human biology and clinical outcomes. CellType targets this translational gap: its core use case is helping pharmaceutical and biotech teams identify which preclinical findings are most likely to survive contact with patients, thereby reducing R&D risk and improving the probability of clinical success. The company also frames clinical and translational prediction as a key way to de-risk discovery and development.
The killer application is patient-level prediction before a trial or major experiment: rather than relying only on mice or cell lines, CellType aims to simulate what will happen in patients, including drug response, toxicity, patient variation, diagnostics, and resistance. Its partnership with Senhwa illustrates the commercial use case—using AI-driven validation to expand the potential indications and value of an oncology asset while strengthening its licensing prospects.
Product / Service
CellType is building an agentic drug company around foundation models that learn human biology and AI agents that can operate across the drug-discovery pipeline. Its platform, described as a world model of biological state, learns from cells, perturbations, molecules, and patients. The underlying technology includes Cell2Sentence and the larger C2S-Scale work, which the company presents as the foundation for modeling cellular and molecular states.
The product is delivered as decision support for drug development rather than simply as a retrospective analytics tool. Its stated applications include translational biology, patient-signal analysis, and virtual experiments: selecting the next experiment, connecting molecular state to responders and resistance, and assessing likely clinical behavior. The intended benefit is to make development more predictive, prioritize better experiments, and reduce the cost and failure risk of advancing weak candidates.
Market
CellType competes in AI-enabled drug discovery and development, specifically the emerging category of biological foundation models, agentic drug discovery, and translational or clinical prediction. The evidence does not identify named direct competitors, but positions CellType against conventional discovery workflows that rely heavily on mice, cell lines, and disconnected preclinical data. Its differentiation is the attempt to model human biological state and run an end-to-end discovery workflow with AI agents.
The company appears early-stage rather than demonstrably pre-revenue: the available evidence does not disclose revenue, financing beyond Y Combinator, or signed commercial contract values. It does report meaningful early traction, including work with Top 10 pharmaceutical companies and says every deal has been 100% inbound. CellType is backed by Y Combinator’s Winter 2026 batch, and its strategic MOU with Senhwa makes CX-4945 a flagship real-world case study for validating the platform in oncology drug development.
Founders & Leadership
Funding History
Y Combinator
Recent News
StartupHub.ai profiled CellType as a two-person YC W2026 company building an agentic drug-discovery platform on a 27-billion-parameter biological foundation model. The article describes AI agents running discovery workflows and notes CellType’s March 2026 strategic MOU with Senhwa Biosciences.
Senhwa Biosciences announced a strategic memorandum of understanding with CellType to integrate CellType’s proprietary AI platform into the clinical development and global commercialization strategy for Silmitasertib (CX-4945). CellType will also use CX-4945 as a flagship case study for validating its AI platform.
Tracxn reports that CellType raised total funding of $500,000 across one round, identifying the latest round as a Seed round dated January 1, 2026. The profile does not disclose the specific round amount.
Active Roles
2Business Model
CellType appears to use a B2B enterprise model, providing pharmaceutical and biotech customers access to its biological world model, AI agents, and drug-development applications through commercial partnerships. Public sources confirm a B2B pharmaceutical platform and strategic integrations, but do not disclose subscription, usage, licensing, or partnership pricing.